G-BA grants Trobalt reassessment

Germany's Federal Joint Committee (G-BA) granted a request from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for a new benefit assessment of epilepsy drug Trobalt retigabine. GSK now has three months to su...